Bibliographie (2546)
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.
mercredi, 30 juin 2021 12:20 Écrit par Zouhair SouissiPulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome – European Heart Journal
The post Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. appeared first on Links Medicus.
Consensus Statement: The role of lung ultrasound in COVID-19 disease.
mercredi, 30 juin 2021 12:20 Écrit par Zouhair SouissiThe role of lung ultrasound in COVID-19 disease – Insights into Imaging
The post Consensus Statement: The role of lung ultrasound in COVID-19 disease. appeared first on Links Medicus.
Covid: Masks upgrade cuts infection risk, research finds.
mercredi, 30 juin 2021 12:20 Écrit par Zouhair SouissiCovid: Masks upgrade cuts infection risk, research finds – BBC
The post Covid: Masks upgrade cuts infection risk, research finds. appeared first on Links Medicus.
IHME COVID-19 model has been updated for over 200 world locations.
mardi, 29 juin 2021 15:31 Écrit par Zouhair SouissiCOVID-19 Projections – Institute for Health Metrics and Evaluation Video: Insights from IHME’s latest COVID-19 model update Commentary on Twitter ? NEW ✨ Our COVID-19 model has been updated for over 200 world locations ? ? ? ? (https://t.co/5biAggRz1T) ? Full video: https://t.co/wLGeAiiYhy? PDFs with explanations of country-specific projections: https://t.co/9KQxWwhQqx pic.twitter.com/8sSEzyXEf8 — Institute for […]
The post IHME COVID-19 model has been updated for over 200 world locations. appeared first on Links Medicus.
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.
mardi, 29 juin 2021 12:10 Écrit par Zouhair SouissiIvermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – Clinical Infectious Diseases Related: Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
The post Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”. appeared first on Links Medicus.
![[Preprint] 3rd AstraZeneca shot gives strong immunity.](/media/k2/items/cache/01f69c1f9473a51d2a7c462a87724eec_M.jpg)
[Preprint] 3rd AstraZeneca shot gives strong immunity.
mardi, 29 juin 2021 12:10 Écrit par Zouhair SouissiStudy: 3rd AstraZeneca shot gives strong immunity – Reuters Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet
The post [Preprint] 3rd AstraZeneca shot gives strong immunity. appeared first on Links Medicus.
SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.
mardi, 29 juin 2021 12:10 Écrit par Zouhair SouissiSARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical Related: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”. Commentary on Twitter (thread – click for more) Just published @natureA […]
The post SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting. appeared first on Links Medicus.
Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.
mardi, 29 juin 2021 12:10 Écrit par Zouhair SouissiThrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine Commentary: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre
The post Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine. appeared first on Links Medicus.
Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
mardi, 29 juin 2021 12:10 Écrit par Zouhair SouissiSafety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases Invited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases Commentary on Twitter NEW—A phase 1/2 clinical trial […]
The post Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years. appeared first on Links Medicus.
Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.
lundi, 28 juin 2021 12:23 Écrit par Zouhair SouissiClinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis – JAMA Network Open Commentary: Did Covid-19 take your taste and smell? Here’s when they may return – CNN AND Lost Sense of Smell Returns for Almost All COVID Survivors – HealthDay
The post Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis. appeared first on Links Medicus.
